Patrick W Sullivan1, Vahram H Ghushchyan2,3, Jonathan D Campbell2, Gary Globe4, Bruce Bender5, David J Magid6,7. 1. a School of Pharmacy, Regis University , Denver , CO , USA. 2. c Center for Pharmaceutical Outcomes Research, Department of Clinical Pharmacy , University of Colorado Aurora , CO , USA. 3. d American University of Armenia , Yerevan , Armenia. 4. e Amgen, Inc. , Thousand Oaks , CA , USA. 5. f Department of Pediatrics , National Jewish Health , Denver , CO , USA. 6. b Institute for Health Research, Kaiser Permanente Colorado , Denver , CO , USA. 7. g Colorado School of Public Health, University of Colorado , Denver , CO , USA.
Abstract
BACKGROUND: Previous studies have shown an association between cost and poor asthma control. However, longitudinal studies of general populations are lacking. OBJECTIVE: To examine the cost of poor asthma control and exacerbations across a broad spectrum of asthma patients. METHODS: The Observational Study of Asthma Control and Outcomes (OSACO) was a prospective survey of persistent asthma patients in Kaiser Colorado in 2011-2012. Patients received a survey 3 times in one year, which included the Asthma Control Questionnaire (ACQ) and questions on exacerbations. Self-reported exacerbations were compared to actual oral corticosteroid (OCS) use. Regression analyses examined the association of control (ACQ-5 scores) and exacerbations with healthcare expenditures, controlling for sociodemographics and smoking. Analyses of expenditures used Generalized Linear Models (GLM) with log-link. RESULTS: 2681 individuals completed at least one survey; 1799 completed all three. ACQ-5 scores were associated with higher all-cause and asthma-specific expenditures across all categories of costs (medical, outpatient, ER, pharmacy) except for inpatient expenditures. Each 1-point increase in the ACQ-5 score (i.e., worse control) was associated with a corresponding increase in all-cause annual healthcare and asthma-specific expenditures of $1443 and $927 ($US 2013). Asthma exacerbations with documented OCS use were associated with an increase of $3014 and $1626 over 4 months, while self-reported exacerbations were $713 and $506. CONCLUSION: Results demonstrate that poor asthma control and exacerbations are strongly associated with higher healthcare expenditures. Results also confirm that collection of validated measures of control such as the ACQ-5 may provide valuable information toward improving clinical and economic outcomes.
BACKGROUND: Previous studies have shown an association between cost and poor asthma control. However, longitudinal studies of general populations are lacking. OBJECTIVE: To examine the cost of poor asthma control and exacerbations across a broad spectrum of asthma patients. METHODS: The Observational Study of Asthma Control and Outcomes (OSACO) was a prospective survey of persistent asthma patients in Kaiser Colorado in 2011-2012. Patients received a survey 3 times in one year, which included the Asthma Control Questionnaire (ACQ) and questions on exacerbations. Self-reported exacerbations were compared to actual oral corticosteroid (OCS) use. Regression analyses examined the association of control (ACQ-5 scores) and exacerbations with healthcare expenditures, controlling for sociodemographics and smoking. Analyses of expenditures used Generalized Linear Models (GLM) with log-link. RESULTS: 2681 individuals completed at least one survey; 1799 completed all three. ACQ-5 scores were associated with higher all-cause and asthma-specific expenditures across all categories of costs (medical, outpatient, ER, pharmacy) except for inpatient expenditures. Each 1-point increase in the ACQ-5 score (i.e., worse control) was associated with a corresponding increase in all-cause annual healthcare and asthma-specific expenditures of $1443 and $927 ($US 2013). Asthma exacerbations with documented OCS use were associated with an increase of $3014 and $1626 over 4 months, while self-reported exacerbations were $713 and $506. CONCLUSION: Results demonstrate that poor asthma control and exacerbations are strongly associated with higher healthcare expenditures. Results also confirm that collection of validated measures of control such as the ACQ-5 may provide valuable information toward improving clinical and economic outcomes.
Entities:
Keywords:
Asthma Control Questionnaire; Medical expenditures; asthma control; exacerbations; oral corticosteroids
Authors: R Brett McQueen; Danielle N Sheehan; Melanie D Whittington; Job F M van Boven; Jonathan D Campbell Journal: Pharmacoeconomics Date: 2018-08 Impact factor: 4.981
Authors: Delesha M Carpenter; Courtney A Roberts; Adam J Sage; Johnson George; Robert Horne Journal: Curr Allergy Asthma Rep Date: 2017-03 Impact factor: 4.806
Authors: Nicole M Wagner; Debra P Ritzwoller; Marsha A Raebel; Glenn K Goodrich; Peter J Cvietusa; Diane K King; Jo Ann Shoup; Bruce G Bender Journal: Transl Behav Med Date: 2021-04-07 Impact factor: 3.046
Authors: Emmely W de Roos; Lies Lahousse; Katia M C Verhamme; Gert-Jan Braunstahl; Johannes J C C M In 't Veen; Bruno H Stricker; Guy G O Brusselle Journal: ERJ Open Res Date: 2021-07-12
Authors: Eugene R Bleecker; Andrew N Menzies-Gow; David B Price; Arnaud Bourdin; Stephen Sweet; Amber L Martin; Marianna Alacqua; Trung N Tran Journal: Am J Respir Crit Care Med Date: 2020-02-01 Impact factor: 21.405
Authors: Job J M H van Bragt; Stefania Principe; Simone Hashimoto; D Naomi Versteeg; Paul Brinkman; Susanne J H Vijverberg; Els J M Weersink; Nicola Scichilone; Anke H Maitland-van der Zee Journal: Metabolites Date: 2021-12-15